Bayer rejects WirtschaftsWoche report on Dicamba lawsuits
(Source: Bayer Company News)
Source: Bayer Company News - August 17, 2018 Category: Pharmaceuticals Source Type: news
Bayer: Conditions for beginning Monsanto integration fulfilled
Legal remedies against jury verdict in California announced (Source: Bayer Company News)
Source: Bayer Company News - August 16, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives approval of new treatment regimen for Eylea ® in the EU (for specialized target groups only)
New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more (Source: Bayer Company News)
Source: Bayer Company News - August 1, 2018 Category: Pharmaceuticals Source Type: news
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease (for specialized target groups only)
Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events (Source: Bayer Company News)
Source: Bayer Company News - July 27, 2018 Category: Pharmaceuticals Source Type: news
Bayer Animal Health and Mitsui Chemicals Agro sign global license agreement
Bayer to expand its strong parasiticide portfolio for companion animals with new compounds derived from MCAG ’s chemical library / License agreement is the result of the long-term collaboration between Bayer and MCAG (Source: Bayer Company News)
Source: Bayer Company News - July 4, 2018 Category: Pharmaceuticals Source Type: news
Bayer concludes refinancing of the Monsanto acquisition by placing bonds with a volume of 5 billion euros
Issue of four tranches with maturities of 4 to 11 ½ years was more than four times oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - June 19, 2018 Category: Pharmaceuticals Source Type: news
Bayer issues new bonds with a volume of 15 billion U.S. dollars
Successful international placement secures long-term financing of the Monsanto acquisition / Issue of eight tranches with maturities of three to 30 years was approximately three times oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - June 19, 2018 Category: Pharmaceuticals Source Type: news
Bayer closes Monsanto acquisition
(Source: Bayer Company News)
Source: Bayer Company News - June 7, 2018 Category: Pharmaceuticals Source Type: news
Bayer plans closing of Monsanto acquisition on June 7
Largest acquisition in company history to double size of agriculture business / Leading innovation engine in agriculture with pro forma R&D investment of 2.4 billion euros in 2017 / Transaction anticipated to generate significant value / Bayer strengthens commitment to sustainability and stakeholder engagement / Bayer to remain company name (Source: Bayer Company News)
Source: Bayer Company News - June 4, 2018 Category: Pharmaceuticals Source Type: news
U. S. Department of Justice conditionally approves Bayer & #8217;s proposed acquisition of Monsanto
Operations of Bayer and Monsanto to be integrated as soon as divestments to BASF have been accomplished (Source: Bayer Company News)
Source: Bayer Company News - May 29, 2018 Category: Pharmaceuticals Source Type: news
U.S. FDA accepts larotrectinib New Drug Application and grants priority review (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - May 29, 2018 Category: Pharmaceuticals Source Type: news
Bayer is making good progress strategically
Acquisition of Monsanto expected to be closed in the near future / 2017 sales and earnings at the prior-year level / Dividend to be raised for the eighth time in succession– to 2.80 euros per share / Start to fiscal 2018 overshadowed by currency effects (Source: Bayer Company News)
Source: Bayer Company News - May 25, 2018 Category: Pharmaceuticals Source Type: news
